Circulation Reports
Online ISSN : 2434-0790

This article has now been updated. Please use the final version.

Risk Factors and Prognostic Significance of Non-Perioperative Atrial Fibrillation in Lung Cancer Patients
Tsukasa OshimaHiroshi Akazawa Junichi IshidaHiroshi KadowakiAkito ShindoTomomi UedaYosuke AmanoKousuke WatanabeKatsuhito FujiuHidenori KageIssei Komuro
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML Advance online publication

Article ID: CR-25-0136

Details
Abstract

Background: The incidence of atrial fibrillation (AF) is high in lung cancer patients, but the clinical and prognostic significance of AF during the non-perioperative period is unknown.

Methods and Results: We performed a retrospective single-center cohort study of consecutive patients diagnosed with primary lung cancer. Of the 383 patients included in this study, 27 (7.04%) developed AF during the non-perioperative period (median follow-up 1.68 years). At the baseline, the AF group had a significantly higher prevalence of age ≥70 years or older, diabetes, heart diseases, chronic kidney disease, and high C-reactive protein (CRP) (>0.6 mg/dL). Multivariate analysis using propensity scores showed that high CRP was an independent risk factor for developing AF (odds ratio 3.08; 95% confidence interval 1.17–8.06; P=0.022). Although most (81.5%) of the AF group had no or mild symptoms, the overall survival rate was significantly lower in the AF than non-AF group. Body mass index ≤25.4 kg/m2was associated with lower survival rate in the AF group, but not in the non-AF group.

Conclusions: In lung cancer patients, the incidence of AF was high during the non-perioperative period, and high CRP was an independent risk factor for developing non-perioperative AF. Although the symptoms were milder, non-perioperative AF was associated with a higher risk of all-cause mortality, and BMI had significant predictive value for mortality.

Fullsize Image
Content from these authors
© 2025, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top